MENU Problem Solver. Partner. Working with healthcare providers, on a mission to advance transformative treatments for people living with serious and rare diseases. Now approved. Click here for prescribing and safety information. Now approved in the EU. Click here for full summary of product characteristics. Waylivra is not approved for any use and is not commercially available in the United States or other markets outside the European Union. Our Commitment At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation. Our Programs Cardiometabolic Lipid Disorders These disorders are complex, with a multitude of risk factors related to many diseases, rare and relatively common, including pancreatitis, diabetes, liver disease, and multiple forms of cardiovascular disease. Hereditary Transthyretin (TTR) Amyloidosis TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease. More about Our Programs Learning about hereditary transthyretin (TTR) amyloidosis TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease. Visit hattrchangethecourse.com Learning about familial chylomicronemia syndrome (FCS) FCS is a severe and rare disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitis Visit FCSFocus.com Careers | Privacy Policy | Terms of Use | Contact | Compliance Governance Documents Akcea Therapeutics 22 Boston Wharf Road, 9th Floor, Boston MA 02210 (617) 207-0202 info@akceatx.com © 2021, all rights reserved Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below. Go to ionispharma.com